Hodgkin bo'lmagan T-hujayrali limfoma kabi etuk T-hujayrali o'smalar yuqori invaziv va dori-darmonlarga chidamli bo'lib, bemorlar ko'pincha yomon prognozga ega. Yaqinda ikkita maqoladan iborat "Tabiat" turkumida Xodgkin bo'lmagan T-hujayrali limfoma patogenezining yangi talqini nashr etildi, bu esa ushbu turdagi malign limfoma uchun yangi davolash usullarini samarali ishlab chiqish uchun yangi yo'nalishni ta'minlaydi.
In the first study, the Wartewig team used the fusion protein ITK-SYK to construct a transgenic mouse model of late-onset T-cell lymphoma (Nature. Doi: 10.1038 / nature24649), and found that the single or double copy of the PDCD1 gene encoding the PD1 protein was deleted. T cell lymphoma undergoes rapid malignant transformation and accelerates the death of the mouse model. In addition, the application of PD1 or PD-L1 inhibitors can produce similar effects. The related mechanism is that PD1 up-regulates PTEN expression and inhibits the tumor malignant proliferation pathway PI3K.
In another article, Maciocia et al. Applied chimeric antigen receptor T cell immunotherapy (CAR-T) therapy (Nat Med. Doi: 10.1038 / nm.4444) to construct CAR-T cells that specifically target TRBC1 but not TRBC2 To treat TRBC1-positive T-cell carcinoma. While killing tumor cells, leaving enough T cells to fight infection. The clinical trial of this method will be officially launched in 2018.
Nature katta muharriri Megan Kallining ta'kidlashicha, yuqorida qayd etilgan muhim topilmalar etuk T-hujayralardagi o'smalarni davolash uchun yangi davolash strategiyasini taqdim etadi va bu o'smalar PD1 yoki PDL1 inhibitörleri bilan davolash uchun mos emasligini ogohlantiradi.
